The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The role of growth factors in the pathogenesis of diabetic retinopathy
Abstract
Diabetic retinopathy (DR) is the most severe of several ocular complications of diabetes. The earliest clinical signs of DR are microaneurysms and haemorrhages. Later signs include dilated, tortuous irregular veins and retinal non-profusion, leading to retinal ischaemia that ultimately results in neovascularisation. Diabetic macular oedema, which involves the breakdown of the blood-retinal barrier, also occurs and is responsible for a major part of vision loss, particularly in Type 2 diabetes. The pathogenesis of DR is very complex. Many biochemical mechanisms have been proposed as explanations for the development and progression of DR. Chronic hyperglycaemia leads to oxidative injury, microthrombi formation, cell adhesion molecule activation, leukostasis and cytokine activation. Next, ischaemia-mediated overexpression of growth factors and cytokines occurs. These factors include vascular endothelial growth factor, insulin-like growth factor-1, angiopoetin-1 and -2, stromal-derived factor-1, fibroblast growth factor-2 and tumour necrosis factor. Because of the complex interplay between these factors, targeting a single growth factor will be unlikely to result in therapeutic inhibition of angiogenesis. These growth factors no doubt act in synergy to mediate the steps of angiogenesis, including protease production, endothelial cell proliferation, migration and tube formation. This review attempts to provide an overview of perspectives regarding the pathogenesis of this disease. The focus, however, is on describing the unique features of selected relevant factors and how each growth factor may act in a synergistic manner with other factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Anti-VEGF strategies are being explored in clinical trials for patients with aberrant ocular neovascularisation [59-63].”
BackgroundIntegrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Interleukin-8 as a macrophage-derived mediator of angiogenesis
Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., Elner, S. G., & Strieter, R. M. (1992) · Science · doi:10.1126/science.1281554 · Cited by 2,135 · cited 1×
“IL-8 is a mitogen and chemotactic for endothelial cells [102].”
BackgroundIsolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81812-7 · Cited by 1,989 · cited 1×
“These supporting cells would typically provide the ang-1 protein that then acts on TIE-2 receptors present on endothelial cells [92,93].”
BackgroundLazarini, F., Tham, T. N., Casanova, P., Arenzana‐Seisdedos, F., & Dubois‐Dalcq, M. (2003) · Glia · doi:10.1002/glia.10139 · Cited by 280
Insulin-Like Growth Factors in the Fed and Fasted States*
MERIMEE, T. J., ZAPF, J., & FROESCH, E. R. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-55-5-999 · Cited by 228
Cited by
Diabetic Retinopathy: Vascular and Inflammatory Disease
Semeraro, F., Cancarini, A., dell’Omo, R., Rezzola, S., Romano, M. R., & Costagliola, C. (2015) · Journal of Diabetes Research · doi:10.1155/2015/582060 · Cited by 424
Altmann, C., & Schmidt, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010110 · Cited by 402
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Ischemic Vascular Damage Can Be Repaired by Healthy, but Not Diabetic, Endothelial Progenitor Cells
Caballero, S., Sengupta, N., Afzal, A., Chang, K.-H., Li Calzi, S., Guberski, D. L., Kern, T. S., & Grant, M. B. (2007) · Diabetes · doi:10.2337/db06-1254 · Cited by 258
Self-citationGood News–Bad News: The Yin and Yang of Immune Privilege in the Eye
Forrester, J. V., & Xu, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00338 · Cited by 153
Metadata
- Authors
- Grant, M. B., Afzal, A., Spoerri, P., Pan, H., Shaw, L. C., & Mames, R. N.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2004-10
- Volume
- 13
- Issue
- 10
- Pages
- 1275-1293
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2165344522
- Cited by
- 171
- References
- 7
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.